We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+15.33%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$294M
AUM Growth
+$106M
Cap. Flow
+$106M
Cap. Flow %
35.98%
Top 10 Hldgs %
58.58%
Holding
91
New
29
Increased
26
Reduced
8
Closed
19

Top Buys

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$27.6M
2
ARYD
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
+$7.56M
3
TVTX icon
Travere Therapeutics
TVTX
+$6.08M
4
MORF
Morphic Holding, Inc. Common Stock
MORF
+$5.85M
5
NAUT icon
Nautilus Biotechnolgy
NAUT
+$5.39M

Top Sells

Rank Stock Value
1
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$29.6M
2
CRIS icon
Curis
CRIS
+$4.71M
3
STRO icon
Sutro Biopharma
STRO
+$2.85M
4
ATNX
Athenex, Inc. Common Stock
ATNX
+$2.21M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$2.2M

Sector Composition

Rank Sector Weight
1 Healthcare 63.48%
2 Financials 2.49%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDNY
26
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.72M 0.92%
175,000
+25,000
+17% +$408K
BGMS
27
Bio Green Med Solution Inc
BGMS
$4.97M
$2.7M 0.92%
106
+73
+221% +$2.06M
CLDX icon
28
Celldex Therapeutics
CLDX
$2.76B
$2.68M 0.91%
130,000
+55,000
+73% +$1.26M
EPIX
29
DELISTED
ESSA Pharma
EPIX
$2.62M 0.89%
+90,000
New +$2.09M
ASND icon
30
Ascendis Pharma A/S
ASND
$16.8B
$2.58M 0.88%
20,000
+10,000
+100% +$1.52M
ASND icon
31
PUT
Ascendis Pharma A/S
ASND
$16.8B
$2.58M 0.88%
+20,000
New +$3.04M
KALV
32
DELISTED
KalVista Pharmaceuticals
KALV
$2.57M 0.87%
100,000
+55,000
+122% +$1.45M
ZYME icon
33
Zymeworks
ZYME
$1.69B
$2.53M 0.86%
80,000
+15,000
+23% +$610K
OBIO icon
34
Orchestra BioMed
OBIO
$224M
$2.52M 0.86%
225,000
+25,000
+13% +$304K
LUNG icon
35
Pulmonx
LUNG
$52M
$2.06M 0.7%
45,000
+25,000
+125% +$1.43M
SWTX
36
DELISTED
SpringWorks Therapeutics
SWTX
$1.99M 0.67%
+27,000
New +$2.11M
RUBY
37
CALL
DELISTED
Rubius Therapeutics, Inc
RUBY
$1.85M 0.63%
+70,000
New +$1.02M
STRO icon
38
Sutro Biopharma
STRO
$367M
$1.82M 0.62%
8,000
-12,000
-60% -$2.85M
QSI icon
39
Quantum-Si Incorporated
QSI
$171M
$1.79M 0.61%
+150,000
New +$1.81M
BFLY icon
40
Butterfly Network
BFLY
$1.74B
$1.68M 0.57%
100,000
+25,000
+33% +$495K
BLUE
41
CALL
DELISTED
bluebird bio
BLUE
$1.51M 0.51%
+3,860
New +$1.9M
MRSN
42
DELISTED
Mersana Therapeutics
MRSN
$1.38M 0.47%
3,400
+1,400
+70% +$679K
PTGX icon
43
Protagonist Therapeutics
PTGX
$8.75B
$1.29M 0.44%
+50,000
New +$1.27M
BLU
44
DELISTED
BELLUS Health Inc.
BLU
$1.15M 0.39%
+300,000
New +$1.14M
IMVT icon
45
CALL
Immunovant
IMVT
$8.09B
$1.12M 0.38%
+70,000
New +$1.85M
TNGX icon
46
Tango Therapeutics
TNGX
$4.37B
$1.11M 0.38%
100,000
– –
LKFT
47
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$964K 0.33%
+12,500
New +$1.15M
CYTK icon
48
Cytokinetics
CYTK
$11.1B
$930K 0.32%
40,000
-30,000
-43% -$641K
VINCW
49
DELISTED
Vincerx Pharma, Inc. Warrant
VINCW
$881K 0.3%
218,000
+28,000
+15% +$113K
GBT
50
DELISTED
Global Blood Therapeutics, Inc.
GBT
$815K 0.28%
20,000
-30,000
-60% -$1.38M
1
2
3 4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return

Affinity Asset Advisors's Q1 2021 Portfolio in Review

As of Q1 2021, Affinity Asset Advisors held 91 positions worth $294M, up 56% from $189M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Affinity Asset Advisors deployed $106M of net new capital in Q1 2021, opening 29 new positions and adding to 26 existing holdings. Its largest new stake was ARYA Sciences Acquisition Corp IV Class A Odinary Shares: 700,000 shares worth $7.33M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 81% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Curis, an estimated $4.71M trimmed.

  • Affinity Asset Advisors's largest Q1 2021 buy was ARYA Sciences Acquisition Corp IV Class A Odinary Shares: 700,000 shares worth $7.33M.
  • Affinity Asset Advisors added most to BridgeBio Pharma in Q1 2021, an estimated $27.6M increase.
  • Affinity Asset Advisors's biggest Q1 2021 reduction was Curis, cutting an estimated $4.71M.
  • Affinity Asset Advisors fully exited Eidos Therapeutics, Inc. Common Stock in Q1 2021, selling an estimated $29.6M.
  • Affinity Asset Advisors's ten largest holdings make up 59% of its $294M portfolio in Q1 2021.
  • Affinity Asset Advisors opened 29 new positions and closed 19 in Q1 2021.
  • Affinity Asset Advisors's portfolio value rose 56% quarter-over-quarter to $294M.

Based on Affinity Asset Advisors's 13F filing for Q1 2021, filed 14 May 2021.